ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGMT vs DSGN // RSI-14 & 200D SMA MOMENTUM

Sagimet Biosciences Inc. (Series A) (NASDAQ) VS. Design Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SGMT 3 — DSGN 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: SGMT
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGMT VS. DSGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGMT DSGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.10% -2.90 DSGN /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -6.21% -7.88% +1.67 SGMT /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 26.00 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 52.3 43.3 +9.00 SGMT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $699.7M $668.4M $31.3M SGMT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGMT REV DSGN REV SGMT GROSS % DSGN GROSS % SGMT FCF DSGN FCF
FY 2025 $159.3M $222.5M — — -$45.6M -$54.6M
FY 2024 $152.5M $174.7M — — -$42.4M -$43.4M
FY 2023 $2.0M $218.9M — — -$23.8M -$58.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGMT // BETA —
DSGN // BETA —